



12 European Biotechs which 'stole the show' at World most Important Cancer Meeting

CANCER MARKET ACCESS


08/06/2016

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It's where one of the biggest oncology events happens – the ASCO Annual Meeting 2016.

Shortly after the AACR annual meeting (with presentations from several European Biotechs), it's time for the ASCO annual meeting. Hosted by the American Society of Clinical Oncology, it ran from 3rd to 7th of June and was an opportunity for many companies to present their latest achievements in cancer therapies.

ASCO 2015 already featured many European breakthroughs, and we also covered some of the work to be presented this year, such as Ganymed's ideal antibodies.

Now that this year's event has come to an end, we will take a closer look at the work of European Biotechs presented at this important conference...



NUCANA

Based in Edinburgh, NuCana is entirely focused on oncology. It develops ProTides, a protective phosphoramidate compound that can be combined with other anti-cancer medicines to bypass resistance mechanisms of the tumor.

After presenting its Phase I trial last year, NuCana is again at ASCO with results from leading candidate Acelarin (NUC-1031). This is an enhanced form of gemcitabine, the current standard therapy for pancreatic cancer.

Acelarin achieved a response rate of 30% with ovarian cancer patients, for whom previous treatments (an average of 3 chemotherapies) hadn't worked.